note prime hit lrp
w/ plenti upsid lever
datapoint meet base busi support top-
line growth potenti upsid new product
repla percuv manta urolift still hyper-growth phase
reimburs stabl head us distributor trend still
shift manag fx cost hit ep growth restructur
mix provid offset co readi execut anoth neotract-lik deal
setup fx manag lrp target well-support host cfo
tom powel iro jake elguicz nick laudico investor meet among
point discuss fx headwind due higher usd
sale deriv eur howev underli growth well support includ vsi
neotract lrp target seem secur addit fx lean top-line
busi also face higher manufactur labor freight cost least
forecast rate hike point interest expens trend toward
rang despit headwind offset come volum feedback
procedur remain posit mix vsi accret urolift adj om-accret
year-end gain restructur see combin move part
support ep rang versu prior
tweak estim fx underli growth intact w/room upsid
revis goe prior reflect greater fx
headwind previous model underli growth target remain
lrp rang continu see adj om expans combin
volum mix restructur benefit importantli revis reflect minim
contribut percuv noth repla manta us despit
latter two potenti market ahead year-end model also reflect
follow-on despit languag suggest sizabl deal plausibl
view stock still confid time urolift look like
substanti bend growth profil higher year come signific room
margin expans strong balanc sheet solid track record deal make see
share pois upsid look ahead combin support outlook
ep higher growth come higher multipl support
upsid valuat case time
gener earn estim reflect cash ep
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
detail setup busi track hit lrp target w/plenti
upsid lever fx asid busi prime hit lrp target earlier year
announc fresh plan call organ top-lin growth
adj om expans combin tax assumpt debt servic
math shake rang although top-lin growth post
analyst day choppi distributor order trend busi continu
rebound year-end inventori trend normal normal season trend take
hold higher volum post deduct potenti upsid flu stock
base-lin growth inclus vsi eventu neotract driver like
point toward underli top-lin growth match lrp target
bottom line fx translat headwind due higher usd big one eur
sale deriv fx headwind assum major
chang rate top higher manufactur feedstock labor
freight cost although recent cross-curr swap bring overal interest
cost co model rate hike next year point interest expens trend
toward rang next year despit headwind offset come
volum feedback procedur remain posit mix vsi accret urolift
adj om accret year-end gain restructur bake bottom-
line would expect ep guid rang
touch lower prevail expect street
distributor still shift near-term headwind distributor headwind
impact earlier year still revers year-end repres modest
tailwind head print big swing factor shift trend among
key us distributor owen minor cardin medlin high level three
work tighten inventori cycl due pressur busi largest
shift seen earlier year co continu reformation/turnaround
importantli omi contract off-set shift purchas cardin
larger extent medlin trend appear continu tighter inventori
level part distributor like continu comfort
underli hospit demand remain strong major shift one player
like off-set two otherswhich would similar play
environ stabl commentari around neotract remain posit
busi look remain hyper-growth phase seen past high
low year-end growth still larg fuel new site
averag add per deeper penetr per practic averag
util still trend procedur per month inclus outlier high-
teen look urolift see sever tailwind continu momentum
may aua guidelin inclus complet doc train median lobe
procedur post remov contraind repres case releas
urolift continu sale market invest combin
reimburs environ larg unchang urolift code still
place multipl implant margin better rezum particularli
asc/hospit set case occur collect driver point toward
growth trend well bake lrp least revenu
meet surpass mileston level
take step back urolift address initi drug-resist patient vertic within
broader total bph market urolift uniqu minim invas
therapi clinic econom front support outlook hyper-
growth year come clinic urolift disrupt versu bph therapi
page
pleas see import disclosur inform page report
sever reason done outpati local anesthesia prostat
tissu complet preserv data show indic incontin
sexual dysfunct versu drug abl therapi econom urolift
reimburs pay higher facil end physician moat
wise ip extend therapi tap code formula
larg well-protect disrupt technolog reminisc impella
execut singl product potenti transform
compani share overtim
new product could add bp growth overtim percuv
see limit market releas earli follow full launch year-end
repla see earli bla submiss possibl follow expedit pma
approv bring market late co also hope manta tavr
evar closur devic need pma panel would pave way late
clearanc despit favor time co littl contribut bake
lrp seem like guid major contribut earlier
clearanc launch could repres upsid collect repla percuv
manta go market opportun rang henc
capabl drive bp growth within lrp depend rate share
 readi anoth neotract-typ transact cornerston
stori past abil acquir nurtur attract
high-growth establish late-stag asset lma vidacar vsi neotract although
compani still midst swallow two largest deal vsi neotract
up-front without mileston balanc sheet profil per year
give ampl room follow-on deal result playbook
continu lrp possibl earli next year indic
bd team busi ever balanc sheet prime execut anoth
neotract-typ transact opportun present understand
anoth transact near complet valuat prove barrier
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
incom statementin million exccept per share datafy dec cc growth cost margin oper oper adj oper margin expens expens incom margin tax net margin net incom ep includ share
page
pleas see import disclosur inform page report
